IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
Charlotte J ImianowskiPaula KuoSarah K WhitesideTeresa von LindeAlexander J WesolowskiAlberto G ContiAlexander C EvansTarrion BairdBenjamin I MorrisNicole E FletcherJie YangEdmund PoonMatthew A LakinsMasahiro YamamotoNeil BrewisMichelle MorrowRahul RoychoudhuriPublished in: Cancer research communications (2024)
The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.